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Abstract
Background: Chronic (systolic) heart failure (CHF) represents a clinical syndrome with high individual and societal 
burden of disease. Multifaceted interventions like case management are seen as promising ways of improving patient 
outcomes, but lack a robust evidence base, especially for primary care. The aim of the study was to explore the 
effectiveness of a new model of CHF case management conducted by doctors' assistants (DAs, equivalent to a nursing 
role) and supported by general practitioners (GPs).
Methods: This patient-randomised controlled trial (phase II) included 31 DAs and employing GPs from 29 small office-
based practices in Germany. Patients with CHF received either case management (n = 99) consisting of telephone 
monitoring and home visits or usual care (n = 100) for 12 months. We obtained clinical data, health care utilisation data, 
and patient-reported data on generic and disease-specific quality of life (QoL, SF-36 and KCCQ), CHF self-care 
(EHFScBS) and on quality of care (PACIC-5A). To compare between groups at follow-up, we performed analyses of 
covariance and logistic regression models.
Results: Baseline measurement showed high guideline adherence to evidence-based pharmacotherapy and good 
patient self-care: Patients received angiotensin converting enzyme inhibitors (or angiotensin-2 receptor antagonists) in 
93.8% and 95%, and betablockers in 72.2% and 84%, and received both in combination in 68% and 80% of cases 
respectively. EHFScBS scores (SD) were 25.4 (8.4) and 25.0 (7.1). KCCQ overall summary scores (SD) were 65.4 (22.6) and 
64.7 (22.7). We found low hospital admission and mortality rates. EHFScBS scores (-3.6 [-5.7;-1.6]) and PACIC and 5A 
scores (both 0.5, [0.3;0.7/0.8]) improved in favour of CM but QoL scores showed no significant group differences 
(Physical/Mental SF-36 summary scores/KCCQ-os [95%CI]: -0.3 [-3.0;2.5]/-0.1 [-3.4;3.1]/1.7 [-3.0;6.4]).
Conclusions: In this sample, with little room for improvement regarding evidence-based pharmacotherapy and CHF 
self-care, case management showed no improved health outcomes or health care utilisation. However, case 
management significantly improved performance and key intermediate outcomes. Our study provides evidence for 
the feasibility of the case management model.
Trial registration number: ISRCTN30822978
Background
Chronic (systolic) heart failure (CHF) is a "common, dis-
abling, deadly, and costly disease" [1] characterised by
hospital admissions due to clinical deterioration. New
treatment and care strategies focus on the prevention of
admissions and improvement of prognosis. Effective
knowledge transfer, for example the adherence of physi-
cians to clinical practice guidelines (CPG) [2] and
patients to treatment regimens [3], is regarded as a key
issue for better patient outcomes.
For improved outcomes, multifaceted interventions are
regarded as essential and many approaches have been
tested. To foster comparability between the related stud-
ies, a taxonomy for chronic disease/case management has
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been suggested accounting for 8 domains (i.e. Patient
population; Intervention recipient and content; Delivery
personnel; Method of communication; Intensity and
Complexity; Environment; Clinical outcomes) [4].
Accordingly, trials have been evaluated with different
focuses, e.g. on changes in the organisation and delivery
of care involving trained nurses [5], pharmacists [6], and
call-centres providing home-based or telephone support
or telemedicine [7,8], with mixed, but promising results.
Ambulatory case management programmes "character-
ized by intensive post-discharge monitoring by a case
manager (usually a nurse)" [4] have demonstrated posi-
tive effects on quality of life and mortality in three to six
months follow-up, but the results are inconsistent for a
longer follow-up [9-13].
Most studies have been conducted with acute patients
enrolled in hospital or shortly after discharge rather than
in primary care. Implementation of a primary care-based
case management model in small-size office-based prac-
tices in Germany, which are led privately by primary care
physicians, is problematical [14,15]. Unlike in many
countries (e.g. UK and the US), practices in Germany do
not have large teams or combinations of skill mix, i.e.
they consist primarily of GPs (61% are solo practitioners
[16]) and doctors' assistants (equivalent to a nursing role)
[17]. German patients do not register with a single gen-
eral practice and have free access to secondary care.
Patients with complex chronic conditions like CHF
receive regular follow-up in specialist care. Nevertheless,
general practices are the primary caregivers and first
point of contact for the majority of heart failure patients
and represent a practical target for delivering case man-
agement interventions aimed at improved outcomes.
A comprehensive framework of chronic illness care
suitable in primary care is the chronic care model (CCM),
which aims to improve the care of patients by integrating
a number of elements into a package designed to foster
more productive interactions between trained, proactive
teams and well-informed, motivated patients. The six ele-
ments that need to be addressed appropriately for provid-
ing high-quality care to patients within this model are
delivery system design, self-management support, deci-
sion support, clinical information systems, community
resources, and healthcare organisation [18].
The aim of this study was to evaluate such a case man-
agement model in comparison to usual care because no
studies have applied a complex primary care-based model
for heart failure patients in Germany.
Methods
Design
This study was part of an exploratory patient-randomised
controlled trial (ISRCTN30822978) conceptualised as a
phase II trial according to the framework of designing
and evaluating complex interventions [14,15]. As such,
qualitative methodologies were undertaken alongside the
trial, to provide supplementary evidence [17,19]. The trial
conformed to the principles outlined in the Declaration
of Helsinki [20] and was approved by the institutional
review boards of the local medical faculty of the univer-
sity and the Medical Association of the federal state
Baden-Württemberg in Germany. The full protocol of
this trial has been published elsewhere [21]. The trial was
an independent project within subproject 10 "Quality of
Life" within the German "Competence Network Heart
Failure", a nationwide research network that bundles the
scientific expertise in a large-scale research network,
sponsored by the Federal Ministry of Education and
Research http://www.knhi.de[22]. Its aims include the
coordination of basic and applied clinical research.
Participants - Recruitment and Assignment
We invited general practitioners (GPs) to participate in
the study through a single mail-out to primary care prac-
tices in one region of Northern Baden, Germany [21].
Interested GPs were eligible for participation if they were
certified as primary care physicians or equivalent and
practiced as statutory health insurance affiliated physi-
cians. To be eligible for inclusion, doctors' assistants, all
employed by the GP, had to have completed at least two
years of their formal training (which consists of a three
years practice-based, vocational training with part-time
attendance at a vocational school) [21].
Eligible patients were adults with ascertained left ven-
tricular systolic dysfunction (left ventricular ejection
fraction of 45% or less), as described in detail elsewhere
[21]. We obtained written informed consent from all par-
ticipating health professionals and patients.
There is an assumed prevalence of patients with at least
moderately impaired left ventricular function of 1% [1].
GPs were expected to include all eligible patients. Antici-
pating the difficulties with screening and patient inclu-
sion, we estimated an average of 5 patients per GP (taking
into account an average list size of 800 patients per GP in
Germany) [23]. Case finding consisted of three strategies,
i.e. brainstorming, opportunistic presentation for consul-
tation by patients, and screening Electronic Medical
Records using ICD-Codes (International Classification of
Diseases) for (potential) heart failure (e.g. I 11* for Hyper-
tensive Heart Disease, I 25* for CHD, I 40 for Myocardi-
tis, I 42* for Cardiomyopathy, I 48* for Atrial Fibrillation
or Flutter, I 50* for Heart Failure; * indicate further speci-
fications).
Practices were recruited between June and November
2006 and practice staff enrolled patients between June
2006 and January 2007. Enrolment of patients with base-
line assessment took place after obtaining informed con-
sent during December 2006 and January 2007. EveryPeters-Klimm et al. Trials 2010, 11:56
http://www.trialsjournal.com/content/11/1/56
Page 3 of 14
participating GP sent a pseudonymised randomisation
document for each patient to an external third party, the
Coordination Centre Clinical Trials (CCCT), which sup-
ported the project in the conceptual and planning phase
(e.g. creation of case report forms, statistical advice) and
operational phase (allocation of patients, data manage-
ment) of the trial. The statistician of the CCCT randomly
assigned patients, based on a computer-generated list, to
either the intervention or usual care on a weekly ongoing
basis. Randomisation was stratified by a "Pocock algo-
rithm" including the number and status of participating
patients per practice and arm. Status  was defined as
whether patients participated in the previously con-
ducted train the trainer study which ended in May 2006
[24]. After randomisation, each randomisation document
was sent back to the practice with the result of the assign-
ment. The nature of the intervention ensured that all par-
ticipants were unblinded once assigned. The third party
concealed intervention allocations from the practice-
based intervention team until shortly before intervention
commencement in February 2007. No interim analyses
were conducted during the observation period, with the
exception of data collection on heart failure medication
for pharmacotherapy feedback. Neither the study statisti-
cians nor the data monitoring committee saw person-
alised data or had any form of contact with study
participants.
Intervention
Patients randomised to the intervention received com-
plex, structured case management by a trained doctor's
assistant (DA) [21]: The design of the intervention
addressed the 4 of the 6 elements of the CCM (delivery
system design, self-management support, decision sup-
port, clinical information systems) [19]: DAs completed 6
hours of theoretical and practical training before con-
ducting regular patient monitoring for 1 year by tele-
phone (patients with NYHA functional status III or IV
three-weekly versus I or II six-weekly) and by 3 home vis-
its for all patients. DAs gave feedback of the results of the
monitoring and screening to their employing GP. The
programme included the use of a CPG, a patient leaflet
according to the national CPG, booklets and tailored dia-
ries. Further details of the intervention have been
described previously [17,19,21]. Additionally, GPs
received graphically depicted individual performance
feedback on evidence-based pharmacotherapy (from data
of baseline documentation) as described in a preceding
trial [24].
For patients in the control (usual care) group, no case
management was applied.
Objectives
In a phase II trial [14,15], we explored whether a compre-
hensive case management intervention would improve
patients' health-related quality of life (QoL), heart failure
self-care, and patient-reported quality of care. Further-
more, we obtained data on hospital admissions and mor-
tality.
Outcome measures
For generic QoL we used the German version of the mul-
tidimensional SF-36 [25]. For disease-specific QoL we
used the German version of the Kansas City Cardiomyo-
pathy Questionnaire (KCCQ) [26], which has been shown
to be a responsive instrument [27].
The SF-36 questionnaire consists of eight dimensions:
Physical functioning, role functioning (physical), bodily
pain, general health perceptions, vitality, social function-
ing, role functioning (emotional), and mental health. SF-
36 scores are converted to a (T-) scale of 0 to 100, with
higher scores indicating a higher QoL. The KCCQ quanti-
fies several health status domains including physical limi-
tations, symptoms (stability, frequency, and burden), self-
efficacy, (mental) quality of life, and social function. Each
scale is transformed to a score of between 0 and 100, with
higher scores indicating superior health status. T o sum-
marise the multiple domains of health status quantified
by the KCCQ, an overall summary score (KCCQ-os) has
been developed that includes the physical limitation,
symptoms, quality of life, and social function domains of
the KCCQ: A mean five-point change in the scales of the
SF-36 [28] and in the KCCQ-os [29] is regarded as clini-
cally significant.
The European Heart Failure Self-care Behaviour Scale
(EHFScBS) is a 12-item, self-administered questionnaire
that covers items concerning the self-care behaviour of
patients with heart failure, for example, daily weighing,
fluid restriction, exercise or contacting a health care pro-
vider. Scores range from 1-5 (12-60), with low  scores
implying better self-care behaviour [30].
The self-administered extended Patient Assessment of
Chronic Illness Care (PACIC-5A) instrument has been
proven to be a practical, reliable and valid tool to measure
quality of chronic care according to the elements of the
CCM [31-34]. The PACIC-5A questionnaire asked
patients 20 questions about important elements of
chronic care, e.g. thinking about treatment choices,
things that can be done to improve health, goals and
treatment plans etc. The 5 subscales of the PACIC
domain are patient activation, delivery system/practice
design, goal setting/tailoring, problem solving/contex-
tual, and follow-up/coordination. Six additional items
measure given behavioural counselling according to the
"5 A" principles (five subscales: assess, advise, agree, assist
and arrange) regarding different chronic conditions
according to the U.S. Preventive Taskforce recommenda-
tions [35,36]. All 26 items are scored on a 5-point Likert
scale ranging from 1 (almost never) to 5 (almost always).Peters-Klimm et al. Trials 2010, 11:56
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Summary scores are generated for chronic care in accor-
dance with the CCM and for the counselling according to
the 5 A, with higher  s c o r e s  i n d i c a t i n g  a  h i g h e r  a c c o r -
dance.
Data collection and management
GPs received an initiation visit by a study nurse including
an introduction to the trial's investigator file. GPs col-
lected and documented clinical data (history, current
clinical status, lab results, ECG, detailed medication for
assessment of guideline adherence etc.), discontinuation
of the study by the patient, and death of the patient on
pre-specified case report forms (CRFs) according to the
Basic Clinical Dataset (BCD) of the Competence Net-
work Heart Failure [22]. NT-proBNP levels at baseline
were determined at the laboratory of the local university
hospital using the Elecsys 2010 analyser from Roche
Diagnostics, Germany. GPs also documented primary
care activity by the number of practice attendances, refer-
rals to a cardiologist, and hospital stays. The CRFs were
sent to the responsible Coordination Centre Clinical Tri-
als (CCCT), where data management was performed
[22]. Parallel to the baseline and follow-up documenta-
tion after 12 months, patient-reported questionnaires
were handed out by DAs. Patients were asked to return
the questionnaires to the relevant DA in a pre-specified
envelope within seven days. DAs then sent the question-
naires back to the study centre to enable the study nurse
to monitor the progress of study documentation and
intervene, e.g. by calling, if necessary. All questionnaires
were then sent to the CCCT by the study team.
Calculation of sample and effect size
The primary objective of this study was to explore the
effectiveness of the CM intervention. Funding precondi-
tions allowed a maximum total sample size of 200 eligible
participants. Assuming an attrition rate of 30% due to
loss to follow-up and death [1], we expected a total of 140
(2 × 70) patients. Given this sample size, an effect of
about 0.45 could be detected using a one-sided t-test with
a significance level of 5% and a power of 80%. Since this
study was a pilot-trial, a one-sided t-test was chosen. The
intervention would only be further investigated if it had a
positive effect on QoL. For quality of life (on the physical
functioning scale [28]) between the interventional and
control arm at 12-months follow-up, an effect size of
about 0.45 corresponds to a clinical difference [37] of
about 9 points with a standard deviation of 20.6 sug-
gested from available recommendations [28].
Statistical methods
Descriptive methods were used for the analysis of the pri-
mary and secondary outcomes, including the calculation
of appropriate summary measures of the empirical distri-
bution (mean, standard deviation, median, minimum,
maximum for continuous variables, and frequencies and
percentages for categorical variables) as well as calcula-
tion of descriptive two-sided p-values for group compari-
sons. For continuous variables, analyses of covariance
(ANCOVA) - adjusted for baseline score, age, gender, and
practice type - were performed. Interaction terms for
group and gender as well as for group and practice type
were included in preliminary models. However, these
effects were uniformly non-significant and were removed
from subsequent models. For binary variables, logistic
regression models were computed. Differences between
the groups regarding variables of health care utilisation
(e.g. practice attendances during follow-up) were analy-
sed using t-test for normally distributed data and using
Mann-Whitney-U-test otherwise. The statistical signifi-
cance was set at 0.05. All analyses were performed using
SPSS version 16.0.2 (SPSS Inc.).
Ethical approval
This study was ethically approved by the Institutional
review boards of the medical faculty of the University of
Heidelberg and Medical Association of the state of
Baden-Württemberg.
Results
Participants' flow and characteristics
Figure 1 shows the flow of participating primary care
physicians and patients through the trial. We approached
a total of 252 physicians from 170 practices in a single
mail-out in June 2006. Of these, 207 did not respond; 12
physicians expressed an interest but did not take part: 1
lost interest, 11 refused due to work load or personal rea-
sons; and 2 physicians failed to find eligible patients.
Therefore, 31 physicians from 29 practices participated.
Between June and November 2006, these physicians
screened 10653 patients for eligibility. Of these, 10397
failed to meet inclusion criteria, 45 eligible patients
refused to participate, 4 did not show up for informed
consent, 3 were admitted to hospital at time of inclusion,
2 died before informed consent, 2 lived "too far away" and
1 was judged by the treating physician as being unfit to
participate.
The 31 participating physicians recruited 199 eligible
patients: 99 patients were randomised to case manage-
ment and 100 to usual care during December 2006 and
January 2007. Once allocated to the case management, 2
participants immediately withdrew their consent render-
ing data collection at baseline impossible. Seventeen
patients were ultimately lost to follow-up, 10 in the case
management group and 7 in the usual care group, 5
patients died in each group (for details see Figure 1).
Table 1 shows the characteristics of practices and staff.Peters-Klimm et al. Trials 2010, 11:56
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Table 2 shows the baseline characteristics for participants
in the intervention and control group regarding socio-
demographic, heart failure specific, comorbidity and
treatment variables.
Interventions
All of the participating DAs attended the training ses-
sions, which were held at the local university.
Adjusted for loss to follow-up (5 patients died and 5
discontinued), 97 patients from the case management
needed to receive 819 (100%) telephone monitoring ses-
sions and 272 (100%) home visits according to their
NYHA functional status: 786 (96.0%) and 269 (98.9%) of
these case management interventions were finally con-
ducted, respectively. Mean durations (SD; range) of the
available overall 740 (90.3%) telephone monitoring ses-
sions and the 3 available overall 256 (94.1%) home visits
were 10 (5; 2-38), and 55 (14; 30-120), 53 (16, 18-90) and
51 (17; 21-90) minutes, respectively. The mean (SD;
range) overall travel time for the home visits took 14 (15;
0-105) minutes. Reporting to the GP took 7 (6; 0-45), and
13 (6; 3-40), 15 (15; 2-75) and 12 (9; 3-50) minutes,
respectively. Missed telephone monitoring sessions were
scheduled in the last month of the follow-up period. Add-
ing up the time for telephone monitoring, travel time,
home visits, and reporting during the 12-month follow-
up resulted in a mean (SD) overall time of 5.2 (2.0) hours
per patient for patients in NYHA functional status I or II
and 6.7 (2.4) hours per patient for patients in NYHA
functional status III.
Table 1: Baseline characteristics of all 31 general 
practitioners (GPs) and 31 doctors' assistants (DAs) from 29 
practices in Northern Baden.
Practice factors at baseline (n = 29)
Practice type
Single 10 (34)
Group practice 19 (66)
Location
rural 14 (48)
suburban 5 (17)
urban 10 (35)
List size (patients per quarter*)
0-1000 6 (19)
1001-1500 11 (36)
>1500 12 (45)
Medical staff (n = 31)
No. of GPs per practice
1 10 (32)
2 14 (45)
3 4 (13)
4 3 (10)
No. of DAs in practice
1-3 11 (35)
4-6 16 (52)
7-11 4 (13)
Mean age of in years (SD)
GPs 50.6 (9.0)
DAs 33.3 (9.6)
Female
GPs 6 (19)
DAs 31(100)
Certification of GPs since mean 
years (SD)
16.3 (9.0)
DAs work experience since mean 
years (SD)
10.8 (9.1)
Figure 1 Flow of participants through the trial.
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Quality of life, behaviour change and quality of chronic 
illness care
The summary scores of the patient-reported outcomes
are displayed in Table 3. Between group differences
(95%CI) at the 12-month follow-up of the physical and
mental component scale of SF-36 were minimal: -0.3 (-
3.0; 2.5) and -0.1 (-3.4; 3.1). The physical functioning scale
of the SF-36 (outcome for sample size calculation, see
methods) showed a small, non-significant improvement
in favour of the case management group (between group
difference: 0.9 (95%CI -5.0; 6.8). With the exception of the
vitality scale (6.6; 95%CI 1.8; 11.3; P = 0.008) there were
no significant group differences in the SF-36 scales (data
not shown in the table).
KCCQ domains were compared for 87 intervention
patients and 93 controls (93% of surviving intervention
patients and 98% of surviving controls) (Figure 1 and
Table 3). Between group differences (95%CI) for the
KCCQ overall summary scores favoured CM: 1.7 (-3.0;
6.4). Significant (positive) time effects were found in the
case management group for self-efficacy (6.5; 95%CI 1.6;
11.3) and social limitation (5.1; 95%CI 0.2; 10.1) (not
shown in the table).
Heart failure self-care behaviour scores (EHFScBS)
were analysable for 65 intervention patients and 78 con-
trols (69% of surviving intervention patients and 82% of
surviving controls), with significant group differences
favouring the case management group (-3.6; 95%CI -5.7; -
1.6, Cohen's d 0.55, P = 0.001, see Table 3).
Significant between group differences were found for
quality of chronic illness care (PACIC) and behaviour
counselling (PACIC-5A) (0.5; 95%CI 0.3-0.7; P = 0.000,
and 0.5; 95%CI 0.3-0.8; P = 0.000), with moderate effect
sizes (Cohen's d 0.7 for each summary score).
Prescribing behaviour, hospital admissions and primary 
care activity
High prescription rates at baseline of drugs with good
evidence for health outcomes (ACE inhibitor or A2RA, β-
blocker, aldosterone antagonists) indicated an antecedent
high guideline adherence by physicians; the increases in
favour of the intervention group were non-significant
(see Additional file 1).
For both groups, heart failure admissions during the
pre-observation period were higher than during follow-
up (36 vs. 35 cases): 18 heart failure admissions were
observed in 11 patients in the intervention group while 9
were recorded by 7 patients in the control group, respec-
tively (Additional file 1); this was a non-significant differ-
ence.
We analysed available primary care activity data during
the observation period for 84 patients of the case man-
agement group and for 89 patients in the control group.
The number of all-cause practice attendances was high at
baseline and increased significantly during the follow-up
in the intervention group (Mean (SD): 27.6 (16.1) vs. 23.9
(19.2), p = 0.02), but neither the number of practice atten-
dances due to heart failure nor of contacts to cardiolo-
gists changed (Additional file 1).
Discussion
Summary of main findings
The intervention failed to improve the overall generic and
disease-specific QoL. Nonetheless, we found significant
improvements regarding patient-reported quality of care
and CHF self-care. While showing low mortality rates
(~5% in both groups) and decreasing heart failure hospi-
tal admissions, there was a significant increase in overall
practice attendances in the intervention group but no
change in contacts with cardiologists. The case manage-
ment intervention was found to be feasible for the doc-
tors' assistants to conduct. The following structured
discussion also refers the exploratory character of the
study and to the taxonomy and framework of chronic ill-
ness care as outlined in the introduction [4,18].
Possible mechanisms of findings and their relation to other 
studies
The relatively high quality of life scores at baseline are
similar to a large, multinational sample of outpatients
with CHF (KCCQ-os: 66.2 ± 20.6) [38]. Our findings
could partly reflect the antecedent high level of chronic
care and self-care in our selected sample of physicians
and patients with stable CHF (with ascertained left ven-
tricular systolic dysfunction). This is supported by the
finding of high evidence-based pharmacotherapy com-
pared to landmark studies [39] and to recent clinical trials
in secondary care [40], and by the level of chronic illness
care and counselling [34], and good self-care (as shown in
Table 3) [6,12,30]. However, given the social structure in
Germany [41], the sample was skewed towards patients in
lower socioeconomic classes but this is typically the case
for primary care [42].
Participation of GP in
Disease management 
programmes
29 (94)
Quality management programme 18 (58)
DA: Doctor's assistant; GP: General practitioner
Values represent number (percentages) of practices unless stated 
otherwise.
*In German ambulatory care, administration is organized by the 
Association of Statutory Health Insurance Physicians in 4 
accounting periods per year, i.e. patients register in a practice 
(formally at a physician) in quarters
Table 1: Baseline characteristics of all 31 general 
practitioners (GPs) and 31 doctors' assistants (DAs) from 29 
practices in Northern Baden. (Continued)Peters-Klimm et al. Trials 2010, 11:56
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Table 2: Baseline comparison of intervention (n = 97) and control group patients (n = 100).
Intervention group (n = 97) Control group (n = 100)
Mean (SD; Range) number of patients per practice 3.2 (1.2; 1-6) 3.2 (1.7; 1-8)
Practice type
single 35 (36.1) 38 (38.0)
group 62 (63.9) 62 (62.0)
List size (patients per quarter)
0-1000 22 (22.7) 26 (26.0)
1001-1500 25 (36.1) 22 (22.0)
>1500 40 (41.2) 42 (42.0)
Male sex 69 (71.1) 74 (74.0)
Mean (SD) age (years) 70.4 (10.0) 68.9 (9.7)
Living alone 26 (26.3) 27 (27.0)
Social class*: (n = 81) (n = 84)
lower, 26 (32.1), 25 (29.8),
middle, 47 (58.0), 52 (61.9),
upper class 8 (9.9) 7 (8.3)
Participation of GP in Train the trainer-trial (GP received an)
intensive educational intervention 14 (14.4) 18 (18.0)
control educational intervention 9 (9.3) 10 (10.0)
no educational intervention 74 (76.3) 72 (72.0)
NYHA-functional class (according to GP)
I 1 (1.0) 5 (5.0)
II 63 (64.9) 67 (67.0)
III 33 (34.0) 27 (27.0)
IV 0 1 (1.0)
Mean (SD) LVEF 35.7 (7.5) (n = 83) 37.6 (6.7) (n = 88)
Main cause of CHF
ischemic 46 (47.4) 47 (47.0)Peters-Klimm et al. Trials 2010, 11:56
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non-ischemic 51 (52.6) 53 (53.0)
Mean (SD) duration (years) of CHF 6.2 (4.6) (n = 79) 6.8 (6.3) (n = 74)
Localisation of CHF
Left 61 (62.9) 67 (67.0)
Left and right 33 (34.0) 31 (31.0)
Unknown 3 (3.1) 2 (2.0)
Cardiovascular interventions
PTCA/Stent (any) 29 (29.9) 36 (36.0)
Bypass (any) 21 (21.6) 21 (21.0)
Pacemaker (right ventricular) 16 (16.5) 16 (16.0)
Pacemaker (biventricular) 7 (7.2) 8 (8.0)
ICD 11 (11.3) 21 (21.0)
Prosthetic heart valve (any) 5 (5.2) 7 (7.0)
Reanimation/Defibrillation 8 (8.2) 6 (6.0)
Medical conditions
Atrial fibrillation 25 (25.8) 29 (29.0)
PAD 17 (17.5) 17 (17.0)
Cerebrovascular disease 22 (22.7) 16 (16.0)
Asthma 7 (7.2) 5 (5.0)
COPD 25 (25.8) 27 (27.0)
Depression 22 (22.7) 17 (17.0)
Cardiovascular risk factors
Diabetes mellitus 32 (33.0) 35 (35.0)
Hypertension 78 (80.4) 78 (78.0)
Table 2: Baseline comparison of intervention (n = 97) and control group patients (n = 100). (Continued)Peters-Klimm et al. Trials 2010, 11:56
http://www.trialsjournal.com/content/11/1/56
Page 9 of 14
Dyslipidemia 63 (64.9) 75 (75.0)
History of infarction before 60 years 18 (18.6) 16 (16.0)
Ex-/smoker (Ex: since at least 6 months) 38/9 (39.2/9.3) 42/14 (42.0/14.0)
Mean number (SD) of drinks per week 3.9 (5.5) 4.7 (9.2)
Creatinine-Clearance: Mean (SD) GFR (ml/min)** 71.6 (31.4) (n = 96) 71.6 (35.1)
Stage of renal dysfunction (n = 96)
GFR ≥ 60 ml/min** 54 (56.2) 57 (57.0)
GFR 30-59 ml/min** 39 (40.6) 37 (37.0)
GFR ≤ 29 ml/min** 3 (3.1) 6 (6.0)
Mean (SD) level of NT-pro-BNP [Median, IQR] in pg/ml 2222.5 (5282.2) [1010.5, 1750] (n = 94) 1828.6 (2914.9) [930, 1712] (n = 96)
Drugs at baseline included:
ACE inhibitor or A2RA 91 (93.8) 95 (95.0)
β-blocker 70 (72.2) 84 (84.0)
ACE inhibitor/A2RA and β-blocker 66 (68.0) 80 (80.0)
Spironolactone/Eplerenone 32 (33.0) 26 (26.0)
Loop diuretics 60 (61.9) 59 (59.0)
Thiazide diuretics 34 (35.1) 41 (41.0)
Cardiac glycosides 25 (25.8) 26 (26.0)
Statins 57 (58.8) 58 (58.0)
Other lipid lowering drugs 11 (11.3) 14 (14.0)
Aspirin (100-300 mg/d) 38 (39.2) 43 (43.0)
Clopidogrel 5 (5.2) 5 (5.0)
Phenprocoumon (Vitamin K Antagonist: equivalent to 
Warfarin)
41 (42.3) 46 (46.0)
Values represent numbers (percentages) of patients unless stated otherwise.
*Social Class according to modified German Winkler-index [57] (lower class: 3-7; middle class: 8-14; upper class: 15-21)
**Estimation of the GFR according to the formula of Cockroft and Gault;
Table 2: Baseline comparison of intervention (n = 97) and control group patients (n = 100). (Continued)Peters-Klimm et al. Trials 2010, 11:56
http://www.trialsjournal.com/content/11/1/56
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Table 3: Mean (SD) scores for groups for generic (SF-36) and disease-specific (KCCQ) quality of life, for self-care (EHFScBS), 
for chronic illness care (PACIC) and health counselling (PACIC-5A) at baseline and at 12 months' follow-up.
Intervention 
(HICMan) group
No Control group No Effect Mean Difference** 
(95% CI), Cohen's d
P value**
SF-36
physical composite score at baseline 36.4 (11.0) 78 36.9 (10.1) 82
at follow-up** 38.0 (8.6) 61 38.3 (8.6) 70 -0.3 [-3.0, 2.5], 0.04 0.857
mental composite score at baseline 45.8 (11.9) 78 47.6 (12.8) 82
at follow-up** 46.5 (9.9) 61 46.6 (9.9) 70 -0.1 [-3.4, 3.1], 0.01 0.929
KCCQ overall summary score at baseline 65.4 (22.6) 96 64.7 (22.7) 100
at follow-up** 68.0 (16.9) 87 66.3 (17.2) 93 1.7 [-3.0, 6.4], 0.10 0.477
EHFScBS* at baseline 25.4 (8.4) 65 25.0 (7.1) 78
at follow-up** 21.2 (6.4) 65 24.8 (6.7) 78 -3.6 [-5.7, -1.6], 0.55 0.001
PACIC overall score at baseline 3.2 (0.9) 89 3.2 (0.8) 97
at follow-up** 3.8 (0.7) 80 3.3 (0.7) 89 0.5 [0.3, 0.7], 0.72 0.000
PACIC-5A overall score at baseline 3.2 (0.9) 89 3.2 (0.9) 97
at follow-up** 3.8 (0.7) 79 3.3 (0.7) 89 0.5 [0.3, 0.8], 0.72 0.000
*Scores range from 12-60; low scores imply better self-care behaviour.
**Based on analysis of covariance (ANCOVA) comparing results between groups at 12 months, adjusted for baseline score, age, gender, practice 
size (single vs. group-practice and list size) without interaction terms. All P values are descriptive.
Observed mortality and heart failure hospitalisation
rates were lower than reported previously [1,13], and a
recent population study shows a trend of decreased mor-
tality attributable to improvements in treatment and pre-
vention [43]. Comparing our study with a meta-analysis
regarding heart failure hospital admissions, rates for case
management vs. usual care were 21.7% (18/83) vs. 10.4%
(9/86) in our study (during 12 months follow-up) and
18.0% (94/523) vs. 29.4% (155/528) (with different follow-
up periods from 3 to 12 months) [11]. While our study
was not powered to this outcome, our findings resemble
those of a recent larger trial, where an intensive disease
management approach increased heart failure hospital
admissions, where the authors concluded that the thresh-
old may have been too low to admit patients to the hospi-
tal [13]. While GPs in our trial received an introductory
clinical practice guideline, behaviour counselling and
pharmacotherapy feedback, they were not specifically
trained in clinical issues relating to thresholds for hospital
admissions and we did not target physicians' behaviour
regarding health care utilisation (referral or hospital
admission). However, our intervention might have caused
the unintended effect of increased hospitalisation (at
higher costs). Whether our observation is an effect of the
intervention cannot be concluded. The observed differ-
ence could have been by chance, due to the Hawthorne
Effect among practice staff and in consequence undue
admissions, or it could be a marker of higher quality of
care. A recent review suggests that disease management
interventions that do not involve efforts to improve phy-
sician care are less effective [44]. In our trial, the physi-
cian care targets were evidence-based pharmacotherapy
(with little room for improvement) and counselling, and
providing a basis for decision through CM with feedback
of information to the physician.Peters-Klimm et al. Trials 2010, 11:56
http://www.trialsjournal.com/content/11/1/56
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Reviews of trials of case management programmes for
patients with CHF have shown mixed results relating to
effects on hospital admissions, mortality and QoL [9-11].
Furthermore, these studies have used a diversity of out-
come instruments, which hinders comparability, e.g. dis-
ease-specific QoL has usually been measured with the
Minnesota living with Heart Failure Questionnaire (MIl-
wHFQ), but generic QoL with the SF-36. Previous studies
have shown variability in the complexity of case manage-
ment (elements of the intervention, integration of care
sectors, education and training of case managers, and
patient empowerment): While overall positive effects on
predominantly disease-specific QoL were found in the
short term (3 to 6 months) follow-up [45-48], the results
for longer follow-ups (9 months to 1 year) were predomi-
nantly neutral [5,12,49-52]: Typically, short-term positive
effects on quality of life were observed in hospitalised and
acutely ill patients, who started with low scores at base-
line enabling the short-term effects in comparison to
control [46-48]. However, our patient sample included
stable chronic systolic heart failure and, in relation to
their age and disease, relatively high quality of life scores
at baseline [28,52]. Regarding generic QoL, our results
suggest that an effect size of 5 points would not be
reached irrespective of the power of the sample size.
Regarding disease-specific QoL, as the upper CI exceeds
5 points (KCCQ-os, see Table 3), results can be regarded
as inconclusive. Nevertheless, QoL did not decrease in
both groups after 1 year, which may be seen as a treat-
ment (and observational) effect, as the natural course of
patients with CHF and normal population shows a
decline in QoL [53].
T w o  p r e v i o u s  r a n d o m i s e d  c o n t r o l l e d  t r i a l s  w i t h  t h e
same (1 year) follow-up period and similar sample sizes,
sex and age profiles showed clinically relevant effects on
QoL and hospital admissions [4,5,12]. They differed from
our study in that the interventions were conducted
mainly in a secondary care setting and the targeted sub-
groups of heart failure patients included patients in more
acute phases, with a higher functional and objective dis-
ease severity (exclusively NYHA III and IV patients,
stronger impaired systolic function). While comorbidity
was similar, our sample showed higher rates of diagnostic
measures and causal therapies indicated by cardiovascu-
lar interventions (PTCA/Stent: 33% vs. 15%, CABG: 21%
vs. 24%, Pacemaker: 24% vs. 9%) (Table 2, [12]). However,
the main novel aspect of our trial relates to the staff who
delivered case management, the intervention content, the
methods of communication, and the intensity and com-
plexity of the intervention [4]: Doctors' assistants and GPs
vs. cardiologists and specialised nurses were involved.
While all programmes had a similar frequency of face-to-
face contacts, the quality and the intensity of the medical
care (e.g. investigations [12]) and educational content
were higher in other studies [5,12,54]. Knowing these
contextual differences with regard to training level and
skills of staff, our intervention included a provider inter-
vention (training of doctors' assistants and introduction
for GPs) and used an elaborated standardised case man-
agement concept enabling doctors' assistants to deliver
case management. It addressed 4 of the 6 domains of the
chronic care model [18]: delivery system design (giving a
doctor's assistant a new role), self-management support
(by counselling and the questions included in the moni-
toring lists), decision support (by patient and physician
guidelines and pharmacotherapy feedback) and clinical
information systems (a registry, patient booklets).
Heterogeneous results regarding QoL have been found
in other primary care-based patient populations: In car-
diovascular high risk patients, improvements in many
scales of generic QoL have been found in primary care-
based interventions [52,55]. However, either the baseline
level was low leaving more room for improvement (physi-
cal functioning) [52], or, if baseline was high, the relative
improvements (in a big sample) were small, and probably
not clinically relevant [55].
Strengths and limitations of the study
The strengths of the study are that many aspects of the
trial promoted high internal validity. Randomisation was
concealed and conducted by a third party; there were rea-
sonably equivalent groups of patients at baseline (with
the exception of differences in the prescription rates of β-
blockers) and good follow-up of patients (93-95% for the
potential primary outcome). However, a weakness is that
it was impossible to blind providers to treatment group,
which may have biased their activity as well as patient
responses to questionnaires. Furthermore, randomisation
was performed at the patient level and all GPs received an
introduction to guideline-oriented management of CHF
and counselling, which may have led to some contamina-
tion between the interventions. While a cluster ran-
domised controlled trial might have mitigated
contamination, we believe any bias was limited because
the main aspects of the intervention were performed by
doctor's assistants and instruments (monitoring lists,
screening instruments, booklets, patient information)
and were delivered to each individual patient. If there was
a bias, we believe that the consequence is that the mea-
sured effect of the intervention may be underestimated.
The baseline characteristics of GPs and the pharmaco-
therapy profile indicate a non-representative sample of
physicians. Moreover, group practices dominate our sam-
ple while, in Germany, solo practices are most common
(64.1%) [56]. Also, participating GPs showed some signs
of above average performance and early adoption of new
methods of practice, for example participating in disease
management programmes. Furthermore, some of thePeters-Klimm et al. Trials 2010, 11:56
http://www.trialsjournal.com/content/11/1/56
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GPs and their patients participated in a preceding trial
aimed at optimisation of heart failure care in general
practice [24]. However, baseline prescription rates were
high also in that study, so it is probably the selection of
patients with ascertained left ventricular systolic dysfunc-
tion and subsequent prescription of evidence-based
pharmacotherapy that is observed.
Considering these aspects of internal and external
validity, further evaluation in a larger representative sam-
ple for robust data is needed to draw definitive conclu-
sions on the effectiveness on QoL, mortality and health
service utilisation.
Conclusions
This phase II trial demonstrates some positive effects of
primary care-based case management on self-care and
quality of care in chronic, stable patients with CHF. The
approach was seen as feasible by practice staff [17,19].
Improved quality of chronic care and CHF self-care
could be regarded as important and targeted outcomes
for an intervention in elderly, multimorbid patients with
CHF in primary care. The CM intervention was success-
fully adapted for primary care settings for this patient
group and while the approach could be augmented by the
use of exercise training programmes which are generally
known to be effective, these are not always feasible. It is
poss ibl e t ha t  pa t ie n ts  wi t h m or e  a dvanc ed CHF m igh t
profit from a CM model approach, with pre-defined
involvement of specialist and integrated care approaches,
including (post-) discharge approaches.
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